Azenta, Inc.

Azenta, Inc. reported Q3 FY2026. EPS came in at $0.16 against a $0.11 consensus, beat by 40.6%. Revenue was $161.2M versus $149.3M expected, beat by 8.0%. Gross margin was 44.9%, up 210 bps from last quarter.

Azenta, Inc. reported a miss on both revenue and EPS estimates for Q2 FY2026, signaling ongoing challenges in the Multiomics segment and a more cautious outlook for the year. The company's financial performance and guidance suggest a need for strategic adjustments to navigate the current market conditions.

Azenta, Inc. cleared revenue expectations by +1.1%, but the print exposed a margin problem that consensus did not price: EPS missed by -18.2% even with revenue ahead. The variant view is that the stock should trade less on the small top-line beat and more on whether management can prove the Q1 gross-margin hit is temporary by Q2 FY2026, because the full-year promise of 3% to 5% organic revenue growth and approximately 300 basis points of adjusted EBITDA margin expansion now requires a visible back-half step-up.

Azenta, Inc. cleared a low Q4 bar, but the investable point is that management paired only 3% to 5% organic revenue growth with 300 basis points of adjusted EBITDA margin expansion and over 30% free cash flow growth. The market likely priced the stock as a sluggish life-science tools recovery story; the print reframes it as an operating-leverage and balance-sheet optionality story, with Multiomics volume growth absorbing near-term margin pressure.

Azenta, Inc. missed revenue by -3.6% but beat EPS by +46.2%, and the market’s likely mistake is treating the margin beat as enough evidence that the turnaround is de-risked. The variant view is more selective: cost and mix are real, especially in Sample Management Solutions, but the reaffirmed FY 2025 growth target now depends on a revenue step-up management itself framed as unusually large.